Effect of vaginal sildenafil on the outcome of in vitro fertilization (IVF) after multiple IVF failures attributed to poor endometrial development.
OBJECTIVE
To evaluate the effects of vaginally administered sildenafil on endometrial thickness and IVF outcome in a large cohort of infertile women with poor endometrial development.


METHODS
Retrospective cohort analysis.


METHODS
Private practice setting.


METHODS
A cohort of 105 infertile women aged <40 years, with normal ovarian reserve and at least two consecutive prior IVF failures attributed to inadequate endometrial development.


METHODS
Patients underwent IVF using a long GnRH-a protocol with the addition of sildenafil vaginal suppositories (25 mg, 4 times per day) for 3-10 days.


METHODS
Peak endometrial development, pregnancy, and implantation rates.


RESULTS
Of 105 patients, 73 (70%; Group A), attained an endometrial thickness of >/=9 mm, whereas 32 (30%; Group B) did not. Implantation and ongoing pregnancy rates were significantly higher for Group A (29% and 45%) than for Group B (2% and 0). Of 11 women in Group B who had embryos transferred in that cycle, only one conception occurred, which resulted in a miscarriage. In Group B, 59% of women had a history of endometritis, compared with 44% in Group A.


CONCLUSIONS
Vaginal administration of sildenafil enhanced endometrial development in 70% of patients studied. High implantation and ongoing pregnancy rates were achieved in a cohort with a poor prognosis for success. Previous endometritis may decrease the response to sildenafil.
Sher
Geoffrey
G
Sher Institute for Reproductive Medicine, Las Vegas, Nevada, USA. gsher@sherinstitute.com
Fisch
Jeffrey D
JD
D000282:Administration, Intravaginal; D000328:Adult; D015331:Cohort Studies; D010064:Embryo Implantation; D004717:Endometrium / Q000187:drug effects / Q000503:physiopathology; D005260:Female; D005307:Fertilization in Vitro; D006801:Humans; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D010879:Piperazines / Q000008:administration & dosage* / Q000627:therapeutic use; D011247:Pregnancy; D018873:Pregnancy Rate; D011687:Purines; D019233:Retreatment; D012189:Retrospective Studies; D000068677:Sildenafil Citrate; D013450:Sulfones; D017211:Treatment Failure; D016896:Treatment Outcome
D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D000068677:Sildenafil Citrate